沙利度胺改善恶性肿瘤化疗患者生活质量分析

Analysis of thalidomide in the quality of life of the malignant tumor patients treated with chemotherapy

目的观察沙利度胺对恶性肿瘤化疗患者生活质量的影响。方法 68例经病理证实的恶性肿瘤化疗患者,随机分为实验组和对照组各34例。实验组在化疗基础上加服沙利度胺,第1周为100mg/d,每晚睡前服用,如果患者可以耐受不良反应,每周增加50mg,直至达到目标剂量200mg/d后维持治疗,如不能耐受加量患者,则维持原剂量治疗。对照组单用化疗。化疗均以3周为一周期,2周期后评价疗效。分别在治疗前和治疗2个周期后评价患者ECOG评分、QOL评分、睡眠质量和饮食情况等。结果实验组KPS评分、QOL评分、睡眠状况、饮食情况改善率分别为64.7%、67.6%、58.8%、55.9%,对照组改善率分别为26.5%、29.4%、17.6%、11.8%,两组比较差异有统计学意义(P<0.05)。实验组的恶心呕吐等消化道反应发生率低于对照组,两组差异具有统计学意义(P<0.05)。结论沙利度胺能够改善恶性肿瘤化疗患者的生活质量。

Objective To observe the effect of thalidomide on the quality of life of patients with malignant tumor undergoing chemotherapy.Methods Total of 68 patients with malignant tumor conifrmed by histo-pathology undergoing chemotherapy were randomly divided into two groups, the trail group 34 cases, the control group 34 cases. Thalidomide was used in the trail group based on the initial dose (100mg/d) in the ifrst week before sleep.If they can tolerate side effects, a weekly increase of 50mg, until the target dose of 200mg/day, if they can not tolerate it, while maintaining the original dose. The control group accepted chemotherapy alone. Chemotherapy was three weeks as a cycle, two cycles were performed.Results The improvement rates of KPS score, QOL score, sleep status, diet status were 64.7%, 67.6%, 58.8%, 55.9%,respectively, The improvement rates of the control group were 26.5%, 29.4%, 17.6%, 11.8%. There were signiifcant differences between two groups (P<0.05). The trail group of gastrointestinal reactions such as nausea and vomiting were lower than the control group, the difference was statistically significant (P<0.05). Conclusions Thalidomide can improve the quality of life in patients with chemotherapy.